GlassScriptPhysician profile
Khatib Jafri
NPI 1811970932
$1,721.10
in general payments reported to CMS, 2019-2025
29 companies · $414 in 2025
The $414 reported for 2025 was more than what 85% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $24.88 · 2022: $284 · 2023: $384 · 2024: $393 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $200.07 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $195.91 | 2019-2025 | Enhertu, Tagrisso, Lynparza |
| Novartis Pharmaceuticals Corporation | $159.01 | 2024-2025 | |
| Lilly USA, LLC | $158.48 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Janssen Biotech, INC. | $128.12 | 2022-2025 | Rybrevant |
| Incyte Corporation | $109.74 | 2022-2025 | Monjuvi, Jakafi, Pemazyre |
| Regeneron Healthcare Solutions, INC. | $103.78 | 2023-2025 | Libtayo, Lynozyfic |
| Genentech USA, INC. | $82.08 | 2019-2025 | Tecentriq, Alecensa, Itovebi |
| Genzyme Corporation | $64.47 | 2022-2023 | |
| Eisai INC. | $62.44 | 2020-2025 | |
| Aveo Pharmaceuticals, INC. | $56.39 | 2022-2023 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $49.66 | 2022-2025 | Onivyde |
| Seagen INC. | $47.12 | 2022-2023 | Tukysa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.73 | 2022-2024 | Gilotrif |
| Myriad Genetic Laboratories, INC. | $24.40 | 2023 | Myrisk |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $24.00 | 2023 | Cosela |
| Pharmacosmos Therapeutics INC. | $22.27 | 2024 | Cosela |
| Taiho Oncology, INC. | $21.88 | 2024 | |
| Daiichi Sankyo INC. | $20.33 | 2025 | Enhertu |
| Tempus Ai, INC | $19.30 | 2024 | |
| Genmab U.S., INC. | $19.13 | 2025 | Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $17.43 | 2024 | Ninlaro |
| Blueprint Medicines Corporation | $16.96 | 2023 | Ayvakit |
| Roche Diagnostics Corporation | $15.54 | 2019 | |
| Tg Therapeutics, INC. | $15.41 | 2022 | |
| Emd Serono, INC. | $14.04 | 2023 | Bavencio |
| Mirati Therapeutics, INC. | $13.99 | 2024 | Krazati |
| E.R. Squibb & Sons, L.L.C. | $12.89 | 2019 | |
| Rigel Pharmaceuticals, INC. | $11.53 | 2024 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khatib Jafri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.